Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer

Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer

US Patent 12220387 · Granted Feb 11, 2025

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist2025
Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist2025
Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist2025
Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist2025
Combination of an immune checkpoint modulator and a complex comprising a cell pe2025
Combination of an immune checkpoint modulator and a complex comprising a cell pe2025
Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist2024
Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist2024
Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide 2022
Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide 2022
Anti-mycobacterial vaccines2017
Cell penetrating peptides2017